Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.71 |
| ▸ | MMP2 | P08253 | 2/20 | 0.71 |
| ▸ | CA1 | P00915 | 1/20 | 0.71 |
| ▸ | MMP1 | P03956 | 1/20 | 0.71 |
| ▸ | MMP9 | P14780 | 1/20 | 0.71 |
| ▸ | MMP8 | P22894 | 1/20 | 0.71 |
| ▸ | MMP13 | P45452 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | CA5A | P35218 | 1/20 | 0.62 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.61 |
| ▸ | F2 | P00734 | 3/20 | 0.60 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.60 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.60 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | DDX3X | O00571 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13590904 | 0.86 | CA2 (0.75) | CA2MMP2CA1MMP1MMP9 | |
| SCHEMBL922350 | 0.83 | CA2 (0.71) | CA2MMP2CA1MMP1MMP9 | |
| SCHEMBL4495753 | 0.83 | CA2 (0.71) | CA2MMP2CA1MMP1MMP9 | |
| SCHEMBL12000920 | 0.83 | CA2 (1.00) | CA2MMP2CA1MMP1MMP9 | |
| SCHEMBL2956545 | 0.83 | CA2 (0.71) | CA2MMP2CA1MMP1MMP9 | |
| Hydrochloric Acid SCHEMBL15619039 | 0.81 | CA2 (0.69) | CA2MMP2CA1MMP1MMP9 | |
| Dinsed SCHEMBL1814194 | 0.81 | KMT2A (1.00) | CA2MMP2CA1MMP1MMP9 | |
| SCHEMBL8099347 | 0.80 | KMT2A (0.72) | CA2MMP2CA1MMP1MMP9 | |
| SCHEMBL1701616 | 0.80 | CA2 (0.67) | CA2MMP2CA1MMP1MMP9 | |
| SCHEMBL9580710 | 0.80 | KMT2A (1.00) | CA2MMP2CA1MMP1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111801327-B | Benzamide compounds | 里科瑞尔姆IP控股有限责任公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-107033043-B | N- replaces benzenesulfonyl-substituted benzene formyl amine compound and its prepares the purposes of drug | 中国人民解放军第二军医大学 | 2019-04-30 | — | — | CN | disclosed |
| CN-107033043-A | N- replaces benzenesulfonyl-substituted benzene formyl amine compound and its prepares the purposes of medicine | 中国人民解放军第二军医大学 | 2017-08-11 | — | — | CN | disclosed |
| EP-2970257-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014158528-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| EP-2576546-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbvie Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| CN-102947283-A | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBOTT LAB | 2013-02-27 | — | — | CN | disclosed |
| US-20120277210-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | ABBOTT LABORATORIES (US) | 2012-11-01 | — | — | US | disclosed |
| EP-2435432-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbott Laboratories (US) | 2012-04-04 | — | — | EP | disclosed |
| WO-2011149492-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | WO | disclosed |
| EP-2376480-A2 | SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | Abbott Laboratories (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010138588-A9 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-05-05 | — | — | WO | disclosed |
| WO-2010138588-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010065865-A2 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277210-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | BCL2, BAX, BCL2L1 | CA2 3015/4885MMP2 560/4885CA1 2706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.